A retrospective analysis of vancomycin pharmacokinetics in Japanese cancer and non-cancer patients based on routine trough monitoring data

Shinobu Omote, Yoshitaka Yano, Tohru Hashida, Satohiro Masuda, Ikuko Yano, Toshiya Katsura, Ken Ichi Inui

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The pharmacokinetics of vancomycin was retrospectively examined based on trough concentrations obtained during routine therapeutic drug monitoring to examine possible pharmacokinetic differences between adult Japanese cancer and non-cancer patients with various degrees of renal function. A total of 231 data points from 65 cancer patients and 41 non-cancer patients were collected, and patients' background, vancomycin dose, and vancomycin clearance estimated by an empirical Bayesian method were summarized. Regarding the patients' characteristics and clinical laboratory test data, no clear differences were found between the two groups. The relationship between vancomycin clearance and creatinine clearance were similar between the groups, suggesting little effect of malignancy on vancomycin clearance. After the sub-group comparisons regarding fluid retention and cancer type, no clear differences were found in the vancomycin clearance versus creatinine clearance relationship. We conclude that the initial dose of vancomycin should not necessarily be adjusted for cancer patients. For individualized vancomycin-based therapy, dose adjustment at the appropriate time is important according to information from routine therapeutic drug monitoring and clinical laboratory tests, and to observations of the efficacy, nephrotoxicity, and other conditions in each patient.

Original languageEnglish
Pages (from-to)99-104
Number of pages6
JournalBiological and Pharmaceutical Bulletin
Volume32
Issue number1
DOIs
Publication statusPublished - Jan 1 2009

Fingerprint

Vancomycin
Pharmacokinetics
Neoplasms
Drug Monitoring
Creatinine
Bayes Theorem
Kidney

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science

Cite this

A retrospective analysis of vancomycin pharmacokinetics in Japanese cancer and non-cancer patients based on routine trough monitoring data. / Omote, Shinobu; Yano, Yoshitaka; Hashida, Tohru; Masuda, Satohiro; Yano, Ikuko; Katsura, Toshiya; Inui, Ken Ichi.

In: Biological and Pharmaceutical Bulletin, Vol. 32, No. 1, 01.01.2009, p. 99-104.

Research output: Contribution to journalArticle

Omote, Shinobu ; Yano, Yoshitaka ; Hashida, Tohru ; Masuda, Satohiro ; Yano, Ikuko ; Katsura, Toshiya ; Inui, Ken Ichi. / A retrospective analysis of vancomycin pharmacokinetics in Japanese cancer and non-cancer patients based on routine trough monitoring data. In: Biological and Pharmaceutical Bulletin. 2009 ; Vol. 32, No. 1. pp. 99-104.
@article{959a21fb771140c597855bef16f20e2a,
title = "A retrospective analysis of vancomycin pharmacokinetics in Japanese cancer and non-cancer patients based on routine trough monitoring data",
abstract = "The pharmacokinetics of vancomycin was retrospectively examined based on trough concentrations obtained during routine therapeutic drug monitoring to examine possible pharmacokinetic differences between adult Japanese cancer and non-cancer patients with various degrees of renal function. A total of 231 data points from 65 cancer patients and 41 non-cancer patients were collected, and patients' background, vancomycin dose, and vancomycin clearance estimated by an empirical Bayesian method were summarized. Regarding the patients' characteristics and clinical laboratory test data, no clear differences were found between the two groups. The relationship between vancomycin clearance and creatinine clearance were similar between the groups, suggesting little effect of malignancy on vancomycin clearance. After the sub-group comparisons regarding fluid retention and cancer type, no clear differences were found in the vancomycin clearance versus creatinine clearance relationship. We conclude that the initial dose of vancomycin should not necessarily be adjusted for cancer patients. For individualized vancomycin-based therapy, dose adjustment at the appropriate time is important according to information from routine therapeutic drug monitoring and clinical laboratory tests, and to observations of the efficacy, nephrotoxicity, and other conditions in each patient.",
author = "Shinobu Omote and Yoshitaka Yano and Tohru Hashida and Satohiro Masuda and Ikuko Yano and Toshiya Katsura and Inui, {Ken Ichi}",
year = "2009",
month = "1",
day = "1",
doi = "10.1248/bpb.32.99",
language = "English",
volume = "32",
pages = "99--104",
journal = "Biological and Pharmaceutical Bulletin",
issn = "0918-6158",
publisher = "Pharmaceutical Society of Japan",
number = "1",

}

TY - JOUR

T1 - A retrospective analysis of vancomycin pharmacokinetics in Japanese cancer and non-cancer patients based on routine trough monitoring data

AU - Omote, Shinobu

AU - Yano, Yoshitaka

AU - Hashida, Tohru

AU - Masuda, Satohiro

AU - Yano, Ikuko

AU - Katsura, Toshiya

AU - Inui, Ken Ichi

PY - 2009/1/1

Y1 - 2009/1/1

N2 - The pharmacokinetics of vancomycin was retrospectively examined based on trough concentrations obtained during routine therapeutic drug monitoring to examine possible pharmacokinetic differences between adult Japanese cancer and non-cancer patients with various degrees of renal function. A total of 231 data points from 65 cancer patients and 41 non-cancer patients were collected, and patients' background, vancomycin dose, and vancomycin clearance estimated by an empirical Bayesian method were summarized. Regarding the patients' characteristics and clinical laboratory test data, no clear differences were found between the two groups. The relationship between vancomycin clearance and creatinine clearance were similar between the groups, suggesting little effect of malignancy on vancomycin clearance. After the sub-group comparisons regarding fluid retention and cancer type, no clear differences were found in the vancomycin clearance versus creatinine clearance relationship. We conclude that the initial dose of vancomycin should not necessarily be adjusted for cancer patients. For individualized vancomycin-based therapy, dose adjustment at the appropriate time is important according to information from routine therapeutic drug monitoring and clinical laboratory tests, and to observations of the efficacy, nephrotoxicity, and other conditions in each patient.

AB - The pharmacokinetics of vancomycin was retrospectively examined based on trough concentrations obtained during routine therapeutic drug monitoring to examine possible pharmacokinetic differences between adult Japanese cancer and non-cancer patients with various degrees of renal function. A total of 231 data points from 65 cancer patients and 41 non-cancer patients were collected, and patients' background, vancomycin dose, and vancomycin clearance estimated by an empirical Bayesian method were summarized. Regarding the patients' characteristics and clinical laboratory test data, no clear differences were found between the two groups. The relationship between vancomycin clearance and creatinine clearance were similar between the groups, suggesting little effect of malignancy on vancomycin clearance. After the sub-group comparisons regarding fluid retention and cancer type, no clear differences were found in the vancomycin clearance versus creatinine clearance relationship. We conclude that the initial dose of vancomycin should not necessarily be adjusted for cancer patients. For individualized vancomycin-based therapy, dose adjustment at the appropriate time is important according to information from routine therapeutic drug monitoring and clinical laboratory tests, and to observations of the efficacy, nephrotoxicity, and other conditions in each patient.

UR - http://www.scopus.com/inward/record.url?scp=59949100613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59949100613&partnerID=8YFLogxK

U2 - 10.1248/bpb.32.99

DO - 10.1248/bpb.32.99

M3 - Article

C2 - 19122288

AN - SCOPUS:59949100613

VL - 32

SP - 99

EP - 104

JO - Biological and Pharmaceutical Bulletin

JF - Biological and Pharmaceutical Bulletin

SN - 0918-6158

IS - 1

ER -